A conformational transition in the adenylyl cyclase catalytic site yields different binding modes for ribosyl-modified and unmodified nucleotide inhibitors.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Bioorganic & Medicinal Chemistry

• Publication date

  2007-04-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.BMC.2007.02.014PMID 17329110PMCID PMC2023969
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Broad Specificity of Mammalian Adenylyl Cyclase for Interaction with 2′,3′-Substituted Purine- and Pyrimidine Nucleotide Inhibitors

  2006cited by this paper
• Differential interactions of G-proteins and adenylyl cyclase with nucleoside 5'-triphosphates, nucleoside 5'-[gamma-thio]triphosphates and nucleoside 5'-[beta,gamma-imido]triphosphates.

  2005cited by this paper
• Structural Basis for the Inhibition of Mammalian Membrane Adenylyl Cyclase by 2 ′(3′)-O-(N-Methylanthraniloyl)-guanosine 5 ′-Triphosphate*

  2005cited by this paper
• Differential interactions of G-proteins and adenylyl cyclase with nucleoside 5′-triphosphates, nucleoside 5′-[γ-thio]triphosphates and nucleoside 5′-[β,γ-imido]triphosphates

  2005cited by this paper
• A seminal study of soluble adenylyl cyclase

  2005cited by this paper
• A docking score function for estimating ligand-protein interactions: application to acetylcholinesterase inhibition.

  2004cited by this paper
• Differential Inhibition of Adenylyl Cyclase Isoforms and Soluble Guanylyl Cyclase by Purine and Pyrimidine Nucleotides*

  2004cited by this paper
• Prostaglandins & other lipid mediators: a new phase, a new team.

  2004cited by this paper
• Mice deficient for soluble adenylyl cyclase are infertile because of a severe sperm-motility defect.

  2004cited by this paper
• Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload

  2003cited by this paper
• 2′(3′)-O-(N-Methylanthraniloyl)-substituted GTP Analogs: A Novel Class of Potent Competitive Adenylyl Cyclase Inhibitors*

  2003cited by this paper
• Distinct Interactions of GTP, UTP, and CTP with GsProteins*

  2002cited by this paper
• Cannabimimetic fatty acid derivatives in cancer and inflammation.

  2000cited by this paper
• Molecular basis for P-site inhibition of adenylyl cyclase.

  2000cited by this paper
• Structure, Mechanism, and Regulation of Mammalian Adenylyl Cyclase*

  1999cited by this paper
• Two-metal-Ion catalysis in adenylyl cyclase.

  1999cited by this paper
• MMFF VI. MMFF94s option for energy minimization studies

  1999cited by this paper
• An adenylate cyclase inhibitor in the treatment of excited psychosis

  1998cited by this paper
• Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function

  1998cited by this paper
• Catalytic mechanism and regulation of mammalian adenylyl cyclases.

  1998cited by this paper
• Prediction of drug binding affinities by comparative binding energy analysis.

  1997cited by this paper
• Fluorescent nucleotide analogs: synthesis and applications.

  1997cited by this paper
• Structure of the adenylyl cyclase catalytic core

  1997cited by this paper
• [18] Fluorescent nucleotide analogs: Synthesis and applications

  1997cited by this paper
• The Conserved Asparagine and Arginine Are Essential for Catalysis of Mammalian Adenylyl Cyclase*

  1997cited by this paper
• Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gsalpha.GTPgammaS.

  1997cited by this paper
• Complexity and diversity of mammalian adenylyl cyclases.

  1996cited by this paper
• Stability of BN and its ions, from BN3+ to BN2−: AN ab initio MRD–CI study

  1995cited by this paper
• Alterations of β-adrenoceptor-G-protein-regulated adenylyl cyclase in heart failure

  1995cited by this paper
• Truncation and alanine-scanning mutants of type I adenylyl cyclase.

  1995cited by this paper
• Prediction of drug binding affinities by comparative binding energy analysis

  1995cited by this paper
• Validation of the general purpose tripos 5.2 force field

  1989cited by this paper
• An all atom force field for simulations of proteins and nucleic acids

  1986cited by this paper
• ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES

  1980cited by this paper

• Novel Modulation of Adenylyl Cyclase Type 2

  2013influential citation
• Discovery and Investigation of Small Molecule Inhibitors of Sulfate Assimilation Pathway as Novel Anti-Latent Tuberculosis Therapy

  2012cites this paper
• Structure-activity relationships for the interactions of 2'- and 3'-(O)-(N-methyl)anthraniloyl-substituted purine and pyrimidine nucleotides with mammalian adenylyl cyclases.

  2011cites this paper
• Inhibition of the adenylyl cyclase toxin, edema factor, from Bacillus anthracis by a series of 18 mono- and bis-(M)ANT-substituted nucleoside 5′-triphosphates

  2011cites this paper
• Structural Basis for the High-Affinity Inhibition of Mammalian Membranous Adenylyl Cyclase by 2′,3′-O-(N-Methylanthraniloyl)-Inosine 5′-Triphosphate

  2011cites this paper
• Molecular analysis of adenylyl cyclase: Bacillus anthracis edema factor exotoxin

  2010cites this paper
• Treating schizophrenia: novel targets for the cholinergic system.

  2010cites this paper
• Capturing adenylyl cyclases as potential drug targets

  2009cites this paper
• Molecular Analysis of the Interaction of Anthrax Adenylyl Cyclase Toxin, Edema Factor, with 2′(3′)-O-(N-(methyl)anthraniloyl)-Substituted Purine and Pyrimidine Nucleotides

  2009cites this paper
• Adenylyl cyclases as innovative therapeutic goals.

  2009cites this paper
• The C1 homodimer of adenylyl cyclase binds nucleotides with high affinity but possesses exceedingly low catalytic activity.

  2009cites this paper
• In memoriam. Angel Ramírez Ortiz (1966-2008).

  2009cites this paper
• Novel inhibitors of anthrax edema factor.

  2008cites this paper
• Whither combine? New opportunities for receptor-based QSAR.

  2007cites this paper